In August 2020, ASCO released a policy statement on health equity that set forth specific recommendations – including addressing underlying institutional and structural barriers to equitable care and education and awareness programs for oncology professionals – to ensure equitable access to care and research. The ASCO Health Equity Committee is developing a concrete strategic plan that the Society will pursue in the coming years, with particular emphasis on increasing workforce diversity, building partnerships with communities affected by disparities, addressing institutional discrimination in the oncology field, and increasing awareness and action on equity issues.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On Monday, August 23, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, and Stand Up To Cancer (SU2C) Health Equity Committee Chair Edith Perez, MD, met virtually to discuss the importance of health equity and the work ASCO and Stand Up To Cancer are doing to increase diversity in cancer research and treatment.
On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.
The American Society of Clinical Oncology (ASCO) released its 2020 Workforce Information Systems (WIS) report, which assembles the latest available data on oncologist supply and demand in the United States to provide a close look at a critical segment of the workforce who care for people with cancer.
The American Society of Clinical Oncology (ASCO) invites you to help shape a new initiative to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. As part of the ASCO and the Association of the Community Cancer Centers (ACCC) recently announced collaboration, ASCO is seeking novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. The ASCO-ACCC Request for Ideas closes August 24, and submissions are being accepted online.
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO), the American Society of Clinical Oncology (ASCO) argues that while progress has been made in raising awareness of disparities and driving research, the cancer community needs to take bolder, more aggressive steps to achieve equity for all patients.
In 2019, ASCO launched an Asia Pacific Regional Council, a group of distinguished oncology leaders from countries in the Asia Pacific region, to advise ASCO on the needs of members in the region and facilitate and encourage member involvement in ASCO’s global activities.
COVID-19 data collection efforts by the American Society of Clinical Oncology (ASCO) were featured in three separate abstracts during the Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer this week. Two of the abstracts highlighted COVID-19 data from PracticeNET, and one abstract that was selected for an oral presentation reported on the ASCO Survey on COVID-19 in Oncology (ASCO) Registry.
The US Food and Drug Administration (FDA) recently finalized four new final Guidance for Industry documents for cancer clinical trial eligibility criteria that describe ways that clinical trials can safely include patients who have historically been excluded. The guidance documents complement ongoing work by ASCO and Friends of Cancer Research (Friends) to eliminate overly restrictive eligibility criteria that can exclude patients from trials without scientific or participant safety justification. Clinical trials provide patients with cancer access to promising investigational therapies – which are sometimes the only treatment option available – and advance clinical care by producing safety and efficacy data about new therapies.
The Association of Clinical Oncology congratulates the eighteen practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second quarter of 2020.
Following the completion of the 2020 Merit-based Incentive Payment System (MIPS) reporting year, the American Society of Clinical Oncology (ASCO) will no longer offer MIPS reporting through the QOPI® Reporting Registry, ASCO’s Qualified Clinical Data Registry (QCDR).
The Centers for Medicare & Medicaid Services (CMS) announced flexibilities for clinicians participating in the 2020 Quality Payment Program (QPP) Merit-based Incentive Payment System (MIPS) who have been impacted by the COVID-19 Public Health Emergency (PHE). Affected clinicians may submit an Extreme & Uncontrollable Circumstances Application to reweight any MIPS performance categories or may apply for the MIPS Promoting Interoperability Performance Category Hardship Exception.
On June 23, 2020, JCO: Oncology Practice published an article on rural cancer care as part of the State of Cancer Care in America series. "Closing the Rural Cancer Care Gap: Three Institutional Approaches," draws from the second event in the State of Cancer Care in America series and supporting literature to summarize the challenges to delivering high-quality care in rural communities, highlight institutional approaches to addressing these challenges, and update ASCO’s rural workforce data.
ASCO expert and Prevention Committee member Noelle LoConte, MD, an associate professor of medicine at the University of Wisconsin (UW) and co-leader of the UW Carbone Cancer Center gastrointestinal disease oriented working group spoke on a panel on “NASH and Liver Cancer” for International NASH Day on June 12.
The Association for Clinical Oncology (ASCO) Board approved its 2020 Advocacy Priorities, which will help ensure that patients with cancer and survivors have access to value-based, high-quality cancer care.